FIELD: medicine.
SUBSTANCE: invention represents immunoglobulins, in particular antibodies, which specifically bind to human interleukin 13 (hIL-13). Claimed are recombinant or transfected mammalian host cell, for cloning, as well as for expression of vectors, coding antibodies. Claimed are antibody-containing pharmaceutical composition, set, containing said pharmaceutical composition and pharmaceutical composition, containing monoclonal antibody against IL-4, such as pascolizumab. Claimed is method ob obtaining antibody, and applications of said antibodies.
EFFECT: antibodies can be used for treatment of various diseases to disorders, responsible for modulation of hIL-13 interaction with human IL-13 receptor.
51 cl, 29 dwg, 22 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
INTERLEUKIN-13-BINDING PROTEINS | 2012 |
|
RU2605327C2 |
INTERLEUKIN-13-BINDING PROTEINS | 2016 |
|
RU2650767C2 |
INTERLEUKIN-13 BINDING PROTEINS | 2007 |
|
RU2472807C2 |
HIGH-AFFINITY HUMAN IL-4 RECEPTOR ANTIBODIES | 2007 |
|
RU2445318C2 |
ANTI-IL-22R-ANTIBODIES | 2017 |
|
RU2758721C2 |
HUMAN ANTIBODIES WITH HIGH AFFINITY TO HUMAN IL-4 RECEPTORS | 2009 |
|
RU2539774C2 |
IMMUNOGLOBULIN WITH DOUBLE VARIABLE DOMAINS AND ITS APPLICATIONS | 2006 |
|
RU2515108C2 |
IL-17A LINKING AGENT AND METHODS FOR USE THEREOF | 2014 |
|
RU2682046C1 |
ANTIBODY AGAINST IL-4R AND APPLICATION THEREOF | 2018 |
|
RU2758091C1 |
POLYPEPTIDE VARIANTS WITH CHANGED EFFECTOR FUNCTION | 2005 |
|
RU2367667C2 |
Authors
Dates
2010-11-20—Published
2005-06-30—Filed